Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H47N5O5S |
Molecular Weight | 613.811 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC=CC(=C2)C(N)=N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
InChI
InChIKey=ISJSHQTWOHGCMM-NDEPHWFRSA-N
InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)/t28-/m0/s1
Molecular Formula | C32H47N5O5S |
Molecular Weight | 613.811 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23379481 | https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C73985DOI: 10.1158/1535-7163.TARG-17-B055 | https://clinicaltrials.gov/ct2/show/NCT00083525 | https://adisinsight.springer.com/drugs/800012176
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23379481 | https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C73985DOI: 10.1158/1535-7163.TARG-17-B055 | https://clinicaltrials.gov/ct2/show/NCT00083525 | https://adisinsight.springer.com/drugs/800012176
Wilex developed WX-UK1 as a specific inhibitor of human trypsin-2, human trypsin-3 and urokinase-plasminogen activator. WX-UK1 participated in phase I clinical trial in combination with capecitabine in advanced malignancies to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics. However, in April 2014, the clinical development of this drug was discontinued, as part of a company restructure.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3159 Sources: DOI: 10.1158/1535-7163.TARG-17-B055 |
75.0 nM [Ki] | ||
Target ID: CHEMBL4551 Sources: DOI: 10.1158/1535-7163.TARG-17-B055 |
19.0 nM [Ki] | ||
Target ID: P00749 Gene ID: 5328.0 Gene Symbol: PLAU Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15170662 |
PubMed
Title | Date | PubMed |
---|---|---|
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. | 2003 Feb |
|
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. | 2004 Jul 20 |
|
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. | 2013 Mar 5 |
|
Activation of the anti-cancer agent upamostat by the mARC enzyme system. | 2013 Sep |
|
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation. | 2015 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23412098
Advanced pancreatic adenocarcinoma: 1000 mg m(-2) of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:25:07 GMT 2023
by
admin
on
Sat Dec 16 01:25:07 GMT 2023
|
Record UNII |
00LOF6890B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
00LOF6890B
Created by
admin on Sat Dec 16 01:25:07 GMT 2023 , Edited by admin on Sat Dec 16 01:25:07 GMT 2023
|
PRIMARY | |||
|
9895193
Created by
admin on Sat Dec 16 01:25:07 GMT 2023 , Edited by admin on Sat Dec 16 01:25:07 GMT 2023
|
PRIMARY | |||
|
220355-63-5
Created by
admin on Sat Dec 16 01:25:07 GMT 2023 , Edited by admin on Sat Dec 16 01:25:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|